{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:28:22Z","timestamp":1785184102135,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vhri.2022.12.001","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T12:53:48Z","timestamp":1673441628000},"page":"100-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis From the Philippine Payer Perspective"],"prefix":"10.1016","volume":"34","author":[{"given":"Miharu Jay M.","family":"Kimwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denese C.","family":"de Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwin Jerome M.","family":"Onda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen L.","family":"Dofitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma. Lorna F.","family":"Frez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse G.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"Francisco D.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette Joy Q.","family":"Almirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark Jayson Q.","family":"Malaluan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristel","family":"Guce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2022.12.001_bib2","first-page":"1","volume":"2","author":"Greb","year":"2016","journal-title":"Psoriasis. Nat Rev Dis Prim"},{"issue":"5","key":"10.1016\/j.vhri.2022.12.001_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ced.12805","article-title":"Prevalence of psoriasis phenotypes among men and women in the USA","volume":"41","author":"Merola","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"9583","key":"10.1016\/j.vhri.2022.12.001_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.vhri.2022.12.001_bib5","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.001_bib6","first-page":"41","article-title":"Demographic and clinical profiles of adult Filipino patients with psoriasis in Davao City: a cross sectional study","volume":"27","author":"Ng","year":"2018","journal-title":"J\u00a0Phil Dermatol Soc"},{"key":"10.1016\/j.vhri.2022.12.001_bib9","series-title":"Pushing psoriasis as a public health program. HEALTHbeat","author":"Roda","year":"2010"},{"key":"10.1016\/j.vhri.2022.12.001_bib10","author":"Feldman"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.001_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.001_bib15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.vhri.2022.12.001_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.vhri.2022.12.001_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis - results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9625","key":"10.1016\/j.vhri.2022.12.001_bib18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.001_bib19","doi-asserted-by":"crossref","first-page":"A20","DOI":"10.1016\/j.jval.2015.03.126","article-title":"A\u00a0new cost-effectiveness framework for modeling psoriasis treatments","volume":"18","author":"Graham","year":"2015","journal-title":"Value Health"},{"issue":"46","key":"10.1016\/j.vhri.2022.12.001_bib20","first-page":"38","article-title":"Etanercept and efalizumab for the\u00a0treatment of adults with psoriasis","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"issue":"7","key":"10.1016\/j.vhri.2022.12.001_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00403-006-0707-8","article-title":"The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients","volume":"298","author":"Mrowietz","year":"2007","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.vhri.2022.12.001_bib22","first-page":"200","article-title":"A\u00a0cost comparison of treatments of moderate to severe psoriasis","volume":"17","author":"Hankin","year":"2005","journal-title":"Drug Benefit Trends"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.001_bib23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/jdv.12576","article-title":"Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)","volume":"29","author":"H\u00e4gg","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2022.12.001_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10198-014-0600-x","article-title":"Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary","volume":"15","author":"Her\u00e9di","year":"2014","journal-title":"Eur J Heal Econ"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.001_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.vhri.2022.12.001_bib26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","article-title":"Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab","volume":"28","author":"Elewski","year":"2017","journal-title":"J\u00a0Dermatol Treat"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.001_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10198-010-0293-8","article-title":"Cost-effectiveness of treatment with etanercept for psoriasis in Sweden","volume":"13","author":"Knight","year":"2012","journal-title":"Eur J Heal Econ"},{"issue":"12","key":"10.1016\/j.vhri.2022.12.001_bib29","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/jdv.15047","article-title":"Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany","volume":"32","author":"Graham","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.001_bib30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13555-021-00675-w","article-title":"Effectiveness and safety of secukinumab for psoriasis in a real-world clinical setting in the Asia-Pacific and Middle East Regions: results from the REALIA study","volume":"12","author":"Foley","year":"2022","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.vhri.2022.12.001_bib31","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40273-020-00937-z","article-title":"Estimating transition probabilities from published evidence: a tutorial for decision modelers","volume":"38","author":"Gidwani","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vhri.2022.12.001_bib32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.vhri.2022.12.001_bib33","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint AAD-NPF guidelines of care for the management of psoriasis with systemic non-biological therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.vhri.2022.12.001_bib34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.vhri.2022.12.001_bib39","author":"Robinson"},{"key":"10.1016\/j.vhri.2022.12.001_bib41","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vhri.2022.12.001_bib42","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2012.06.035","article-title":"Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis","volume":"68","author":"Yeung","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.vhri.2022.12.001_bib43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922002011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922002011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:26Z","timestamp":1761941666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922002011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":31,"alternative-id":["S2212109922002011"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.12.001","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Selected Interleukin Inhibitors Versus Methotrexate for Moderate-to-Severe Plaque Psoriasis From the Philippine Payer Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}